PDGFRB and neoplasm: To address these questions, we used Calu-3 and Calu-6 human NSCLC xenograft models to represent stromal vessel and tumour vessel phenotypes, respectively, and treated tumour-bearing mice with cediranib, a highly potent pan-VEGFR TKI with additional activity against c-Kit, PDGFR and FGFR [15].